DALLAS, Sept. 11, 2006 (PRIMEZONE) -- Complete Care Medical, Inc. (Pink Sheets:CCMI) announces that it has receive a rating of "Attractive" by Equity Stock Analysis (ESA). The report is authored by Senior Research Analyst, Kris Gupta, CFA.
The full report is available at http://www.equitystockanalysis.com
In the report Mr. Gupta writes, "Complete Care Medical Inc. provides low cost alternatives for medication and both durable and disposable medical products and medical supplies. CCMI's primary goal is to become the low cost provider of prescriptions, medical products, and medical supplies for home delivery for individuals and groups. The Company's service will be enhanced by personalized and professional support. CCMI will target disease specific medical niches focusing on high profit equipment and supply needs including urology, diabetes, respiratory, ostomy, and mastectomy.
CCMI is expected to generate revenue of $5 million over the next twelve months by conservative estimates. This revenue stream focuses on the Urology Division of CCMI, the pharmacy, and its DiabetesGOLD division.
CCMI plans to focus on the most profitable sections of the health care industry which are medical supplies and durable medical equipment. It will use its pharmacy as a base from which to launch these divisions which include: urology, ostomy, masectomy, and respiratory. By using the pharmacy as the basis for the operations CCMI will be able to fill all the patient's needs and become a one stop mail order shopping environment for associated equipment and supplies. They intend to offer professional training and advice to their patients and customers as well."
About Complete Care Medical, Inc.
Complete Care Medical Management, Inc. provides patients in all 50 states with lower cost alternatives for disease management, medical supplies and prescription pharmaceuticals. In addition, Complete Care Medical's discount services and medication program offers healthcare payers, healthcare providers, healthcare professionals and patients with easy access to utilization and compliance data in order to improve patient outcomes and improve quality of life.
About Equity Stock Analysis
EQUITY STOCK ANALYSIS ("ESA") is committed to the highest ethical standards and as such is not subject to external pressure that is sometimes experienced to issue biased research. This pressure is avoided by refusing to accept companies that cannot be recommended with objectivity, quality, and accuracy of research. ESA and its Certified Financial Analysts are independent, objective, and have a reasonable and adequate basis for our investment recommendations. ESA has established formal written policies supporting independent and objective analyst research. ESA has senior corporate officer publicly attest, at least annually, to adherence to the policy.
Disclosure: Pentony Enterprises LLC was compensated two million free trading shares from a non-controlling third party for profile coverage. John Pentony, a Principal of Pentony Enterprises, also owns 912,000 shares previously accumulated by buying in the open market. Pentony Enterprises is not a registered investment advisers or a broker/dealer. Pentony Enterprises LLC makes no recommendation that the purchase of securities of companies profiled in this web site is suitable or advisable for any person, or that an investment such securities will be profitable. In general, given the nature of the companies profiled and the lack of an active trading market for their securities, investing in such securities is highly speculative and carries a high degree of risk. All shares - including those previously accumulated in the open market - will be held for at least thirty days from the initial date of publication by Pentony Enterprises, which is August 18, 2006. It is the policy of Pentony Enterprises LLC to sell all shares of this and any company featured. Anyone considering any company we feature in consideration for free trading shares should consider this.